Chris Sandburg
Recent Articles by Chris Sandburg
- CytoDyn’s Preliminary Phase 1b/2 Cancer Results Likely to Receive Breakthrough Therapy Designation (BTD)
- CytoDyn (CYDY) at Crossroads: Past and Current Leadership Collide in Epic Grudgematch
- Enzolytics (ENZC) Takes on HIV Heavyweight Gilead Sciences
- Todos Medical (TOMDF) with a $22 Million Market Cap Taking on Pharma Giant Pfizer for COVID-19 Antiviral
- Aikido Pharma’s (AIKI) Clinical Trial Results Continues to Validates Gilead's $21 Billion Purchase of Immunomedics
- Enzolytics (ENZC) Working With Intel (INTC)
- CytoDyn FDA Letter is Old News - International Still Progressing
- Northwest Biotherapeutics Breadcrumbs Point to ASCO Announcement of Top Line Data
- CytoDyn’s Adjust Course to Emphasize Philippine EUA and Long Haulers
- Kempharm (KMPH) Shareholders Blinded by Short Term Greed Versus Solid Long Term Outlook
Recent Comments by Chris Sandburg
- "The essence of your argument seems to be centered around expectations. NP has clearly missed some self imposed deadlines, but these misses pale in co" on CytoDyn’s Preliminary Phase 1b/2 Cancer Results Likely to Receive Breakthrough Therapy Designation (BTD)